<DOC>
	<DOCNO>NCT02719132</DOCNO>
	<brief_summary>This multicenter , randomise , open-label , crossover , 2-period comparative phase IV study . The primary objective compare effect dapagliflozin 10 mg daily combination metformin daily dose ≤1,500 mg vs. metformin monotherapy dose titrate 2,500 mg/day overall quality life , obesity-specific quality life treatment satisfaction patient type 2 diabetes .</brief_summary>
	<brief_title>Effect DapagliFLOzin Quality Life Patients With Type 2 Diabetes Real Clinical PrActice</brief_title>
	<detailed_description>The study comprise follow phase : Screening , Treatment Period 1 Treatment Period 2 . After screen examination assessment , patient enrol randomly assign equal proportion ( 1:1 ) either study arm : Arm 1 : - Patients take dapagliflozin 10 mg combination metformin ≤ 1,500 mg ( daily dose ) 24 week Treatment Period 1 - Patients metformin monotherapy dose titrate 2,500 mg/day 24 week Treatment Period 2 Arm 2 ( treatment phase reverse order ) : - Patients metformin monotherapy dose titrate 2,500 mg/day 24 week Treatment Period 1 - Patients take dapagliflozin 10 mg combination metformin ≤ 1,500 mg ( daily dose ) 24 week Treatment Period 2 Following randomisation procedure , patient receive investigational product visit schedule Treatment Period 1 . After Randomisation Visit ( Visit 2 ) , patient attend study centre Visits 3 , 4 , 5 ( Day 28 , Day 86 , Day 168 , respectively ) efficacy safety assessment . At Visit 5 ( Day 168 ) , patient receive investigational product require Treatment Period 2 . Further Visits 6 , 7 8 schedule Day 196 , Day 252 , Day 336 , respectively .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>For inclusion study patient fulfil ALL criterion list : 1 . A voluntary informed consent form participation study sign patient prior studyspecific procedure 2 . Male female patient 1874 year age 3 . Diagnosed type 2 diabetes 4 . Therapy metformin stable dose ≤1,500 mg/day least 8 week enrolment 5 . HbA1c &gt; 7.0 % ≤10 % Screening Visit 6 . Cpeptide ≥1.0 ng/ml Screening Visit 7 . Body mass index ≤45.0 kg/m² Screening Visit 8 . For woman childbearing potential use reliable birth control methods 9 . Ability complete studyspecific procedures 10 . Ability complete questionnaire 1 . Type 1 diabetes 2 . Diabetic ketoacidosis Screening 3 . AST and/or ALT &gt; 3 × upper limit normal Screening 4 . Total serum bilirubin &gt; 34.19 μmol/l Screening 5 . Decompensated diabetes mellitus ( HbA1c &gt; 10 % Screening ) 6 . Patients moderate severe renal impairment ( CrCl &lt; 60 ml/min &lt; 60 ml/min/1.73 m2 Screening ) terminal renal insufficiency 7 . Severe concomitant disease severe cardiovascular , renal , hepatic , hematologic , endocrine , mental rheumatic pathology 8 . Malignancy within 5 year enrolment 9 . Acute ( include viral infectious ) diseases within 1 month Screening Visit . 10 . Development severe acute disease study significantly affect benefit/risk ratio subject affect study efficacy/safety assessment criterion 11 . History acute myocardial infarction stroke within 6 month Screening Visit study . Heart failure ( NYHA IIIIV ) 12 . Treatment drug affect glucose homeostasis ( e.g. , systemic glucocorticosteroids ) within 3 month Screening Visit . 13 . For woman childbearing potential positive pregnancy test patient breastfeed plan pregnancy study 14 . History Hepatitis B C HIV 15 . Individual hypersensitivity component investigational product ( dapagliflozin ) 16 . Treatment sodiumdependent glucose cotransporter inhibitor ( SGLT2 ) administer within 3 month prior enrolment plan study . 17 . Loop diuretic administer 3 month Screening Visit plan study . 18 . Hereditary lactose intolerance , lactase deficiency glucosegalactose malabsorption 19 . The patient unable follow study procedure attend study centre schedule study visit go relocate within protocolspecific timeline 20 . The patient subject study within 3 month enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes Mellitus type 2 , dapagliflozin , quality life</keyword>
</DOC>